Zura Bio (ZURA) Competitors

Cullinan Therapeutics (NASDAQ:CGEM) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Do institutionals & insiders hold more shares of CGEM or ZURA?

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 7.2% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 14.2% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is CGEM or ZURA more profitable?

Cullinan Therapeutics' return on equity of -36.56% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-36.56%	-34.82%
Zura Bio	N/A	-49.11%	-40.06%

Which has more volatility and risk, CGEM or ZURA?

Cullinan Therapeutics has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500.

Do analysts prefer CGEM or ZURA?

Cullinan Therapeutics presently has a consensus price target of $26.80, suggesting a potential upside of 227.23%. Zura Bio has a consensus price target of $14.00, suggesting a potential upside of 596.52%. Given Zura Bio's higher possible upside, analysts clearly believe Zura Bio is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zura Bio	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has preferable earnings and valuation, CGEM or ZURA?

Zura Bio is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$167.38M	-$3.23	-2.54
Zura Bio	N/A	N/A	-$45.39M	-$0.70	-2.87

Does the media favor CGEM or ZURA?

In the previous week, Cullinan Therapeutics had 2 more articles in the media than Zura Bio. MarketBeat recorded 17 mentions for Cullinan Therapeutics and 15 mentions for Zura Bio. Cullinan Therapeutics' average media sentiment score of 0.85 beat Zura Bio's score of 0.40 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zura Bio beats Cullinan Therapeutics on 7 of the 13 factors compared between the two stocks.